Marina Pavlovic led Eli Health Raises $12 million in Series A Funding for Testing New Platform

• Marina Pavlovic Rivas-led Eli Health has raised $12 million in funding round, making total funds of $20 million
• The funds will be used for testing a new platform for measuring cortisol levels

A total of $12 million has been raised by Eli Health in its Series A funding round while beginning the testing of its new platform for measuring cortisol levels. Bringing the total funding to $20 million, this recent funding of the company was led by a BDC Capital fund focused on women-led companies, Thrive Venture Fund.

Several other firms also participated which includes existing investor Muse Capital, whose founding partner, Assia Grazioli-Venier, is on Eli Health's board. In addition, Eli Health co-founder and CEO Marina Pavlovic Rivas said in a statement to SBI, “This milestone is extremely meaningful, because to get to this point, it was close to six years of [research and development]. For the first time, people are able to measure their hormones instantly, and this funding enables us to accelerate access to the product and to expand to other biomarkers.”

Moreover, Hormometer is the flagship product of the company that tests saliva for key hormones like cortisol as well as progesterone via a collection device. Later, the product will leverage computer vision models to analyze the sample, returning results and AI-powered trends/recommendations to its mobile app through one’s phone camera.

Marina added, “One in three adults are affected by dysregulation when it comes to cortisol, and that’s true across gender, across ages. We’re starting with that focus, and progesterone will follow shortly.”